Journal: BBA Clinical

Article Title: Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

doi: 10.1016/j.bbacli.2017.05.003

Figure Lengend Snippet: Label-free mass spectrometry data. List of statistically significant discovered proteins using LC-MS analysis. Proteins (in bold) were selected for further validation using ELISAs.

Article Snippet: Four commercially available kits for these four proteins; angiogenin (ANG) [Abcam, UK - ab99970], clusterin (CLU) [R&D system, UK - DCLU00], C-C Motif Chemokine 18 (CCL18) [Abcam, UK - ab100620], and Complement C1q [Abcam, UK - ab170246] were used.

Techniques: Mass Spectrometry, Variant Assay

Journal: BBA Clinical

Article Title: Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

doi: 10.1016/j.bbacli.2017.05.003

Figure Lengend Snippet: ELISA Data. Mean, SD, Area under the curve (AUC) and p -value for each of the new and standard proteins found in the two groups of patients compared.

Article Snippet: Four commercially available kits for these four proteins; angiogenin (ANG) [Abcam, UK - ab99970], clusterin (CLU) [R&D system, UK - DCLU00], C-C Motif Chemokine 18 (CCL18) [Abcam, UK - ab100620], and Complement C1q [Abcam, UK - ab170246] were used.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: BBA Clinical

Article Title: Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

doi: 10.1016/j.bbacli.2017.05.003

Figure Lengend Snippet: Logistic regression analysis data. List of different protein combinations used to establish the best model that can be used as a predictive panel for response to induction therapy containing bortezomib regime.

Article Snippet: Four commercially available kits for these four proteins; angiogenin (ANG) [Abcam, UK - ab99970], clusterin (CLU) [R&D system, UK - DCLU00], C-C Motif Chemokine 18 (CCL18) [Abcam, UK - ab100620], and Complement C1q [Abcam, UK - ab170246] were used.

Techniques:

Journal: Molecular Medicine Reports

Article Title: Proteomics analysis of lung tissue reveals protein makers for the lung injury of adjuvant arthritis rats

doi: 10.3892/mmr.2023.13051

Figure Lengend Snippet: Immunofluorescence results for C1qc, C9 and Clu (×400). (A) Immunofluorescence expression of C1qc. (B) Immunofluorescence expression of C9. (C) Immunofluorescence expression of Clu. Quantitative analysis of immunofluorescence results of (D) C1qc, (E) C9 and (F) Clu proteins. Relative expression of (G) C1qc, (H) C9 and (I) Clu proteins were analyzed by proteomic analysis. *P<0.05 or **P<0.01 vs. CN group in rats. C, complement; CN, control; Clu, clusterin.

Article Snippet: The sections were incubated with primary antibodies against C1qc (1:100; cat. no. A05666; Boster Biological Technology), C9 (1:100; cat. no. K107807P; Beijing Solarbio Science and Technology Co., Ltd.), Clu (1:100; cat. no. 12289-1-AP; Proteintech Group, Inc.) at 4°C overnight and washed with PBS 3 times (5 min each).

Techniques: Immunofluorescence, Expressing